GH - Guardant Health Inc

Buy Momentum: Bearish

Recent News

Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings - Guardant Health ( NASDAQ:GH )

Benzinga • 1 month, 2 weeks ago • score: 0.42

Guardant Health, Inc. GH reported better-than-expected second-quarter financial results and raised its FY25 sales guidance above estimates on Wednesday. Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.

52W High

$68.00

52W Low

$20.14

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.46

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-5.40

EV/Revenue (<3 favorable)

9.90

P/S (TTM) (<3 favorable)

9.05

P/B (<3 favorable)

55.67

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.50%

Institutions (25–75% balanced)

99.10%

Shares Outstanding

124,706,000

Float

119,554,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

828,849,000

Gross Profit (TTM)

520,839,000

EPS (TTM)

-3.35

Profit Margin (>10% good)

-0.50%

Operating Margin (TTM) (higher better)

-0.46%

ROE (TTM) (>15% strong)

-45.84%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.31

Momentum

Bearish momentum

Value

0.8904

1.5507

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025